# VRDN — Viridian Therapeutics Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** VRDN  
**Sources:** 20  
**Published:** 2026-10-27  
**Canonical:** https://app.k3vl4r.com/research/deep-research-vrdn-viridian-therapeutics-inc-catalysts-narrative-risks-9633

---

## Snapshot (as of 2026‑10‑27)

Viridian Therapeutics (NASDAQ: VRDN) — a Healthcare/Biotechnology firm — last traded around **US$24.09, up ~3.2%** on the day, with a **market cap of ~US$2.73B** and a 52‑week range of US$13.18–US$34.29 [[2]](https://www.stoxline.com/quote.php?symbol=VRDN), [[10]](https://stockanalysis.com/stocks/vrdn/), [[11]](https://finance.yahoo.com/quote/VRDN/), [[12]](https://www.marketbeat.com/earnings/reports/2026-11-4-vrdn-stock/). Trailing revenue is ~US$71.1M while the company is still loss‑making (net income ~‑US$334M; EPS TTM roughly ‑US$3.4) [[10]](https://stockanalysis.com/stocks/vrdn/), [[11]](https://finance.yahoo.com/quote/VRDN/). It holds a large cash buffer of ~US$981.5M as of June 30, 2026 [[10]](https://stockanalysis.com/stocks/vrdn/), [[11]](https://finance.yahoo.com/quote/VRDN/). Note that this analysis draws on press releases, equity‑research reports and analyst price targets [LIB‑3], and as with sentiment/news‑driven data these inputs warrant the usual reliability caveats around garbled or stale fields [LIB‑1].

## Recent catalysts (last ~1–3 months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-vrdn-viridian-therapeutics-inc-catalysts-narrative-risks-9633 (free to sign up)._